Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance

Abeona Therapeutics IncTrade
Stanley Black & Decker, Inc.Trade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Stanley Black & Decker, Inc. trades at $103.91 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 37.3× Abeona Therapeutics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOSWK
Market Cap
$421.19M$15.71B
Sector
Health
52-Week High
$7.45$104.00
52-Week Low
$4.17$62.12
Enterprise Value
$276.10M$19.87B
Dividend Yield
3.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Stanley Black & Decker, Inc.

Stanley Black & Decker (SWK) trades at $103.11, up 0.46% today, with a bullish technical signal from moving averages but overbought RSI readings near 80. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.57 exceeding expectations by 30%. Recent news highlights a $1 billion U.S. investment plan and strong institutional buying, while fundamentals show improving margins and debt reduction progress.

SWK presents a mixed outlook: positive earnings momentum and strategic initiatives support upside, but valuation appears stretched with a P/E of 25.4 above sector averages. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is cautious with a hold-heavy rating and $93.67 price target below current levels, suggesting limited near-term upside despite operational improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Stanley Black & Decker, Inc.

Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.

Read more on SWK